Randomized Trial Backs HIF-2a Inhibition in Advanced RCC :

After immunotherapy-TKI failure, belzutifan produces better outcomes versus everolimus

Related Keywords

France , London , City Of , United Kingdom , Madrid , Spain , Lisa Pickering , Albigesl Belzutifan , Laurence Albiges , European Society For Medical Oncology , Gustave Roussy Institute In Villejuif , Database Consortium , International Metastatic , Gustave Roussy Institute , European Society , Medical Oncology , Royal Marsden Hospital , Functional Assessment , Managing Editor , Medpage Today ,